NASDAQ: NVCRNovocure Ltd Stock
$12.05+0.00 (+0%)
Updated Apr 18, 2024
NVCR Price
$12.05
Fair Value Price
$12.04
Market Cap
$1.29B
52 Week Low
$10.87
52 Week High
$83.60
P/E
-6.18x
P/B
3.56x
P/S
3.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$509.34M
Earnings
-$207.04M
Gross Margin
74.8%
Operating Margin
-45.72%
Profit Margin
-40.6%
Debt to Equity
2.16
Operating Cash Flow
-$73M
Beta
1.18
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NVCR Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVCR ($12.05) is overvalued by 0.07% relative to our estimate of its Fair Value price of $12.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NVCR ($12.05) is not significantly undervalued (0.07%) relative to our estimate of its Fair Value price of $12.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NVCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NVCR due diligence checks available for Premium users.
Be the first to know about important NVCR news, forecast changes, insider trades & much more!
NVCR News
Valuation
NVCR fair value
Fair Value of NVCR stock based on Discounted Cash Flow (DCF)
Price
$12.05
Fair Value
$12.04
Overvalued by
0.07%
NVCR ($12.05) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NVCR ($12.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NVCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NVCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.18x
Industry
28.61x
Market
41.33x
NVCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.56x
Industry
3.63x
NVCR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVCR's financial health
Profit margin
Revenue
$133.8M
Net Income
-$47.1M
Profit Margin
-35.2%
NVCR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NVCR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$783.6M
Debt to equity
2.16
NVCR's short-term assets ($1.03B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVCR's short-term assets ($1.03B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVCR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.6M
Investing
$98.5M
Financing
$1.9M
NVCR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVCR vs Medical Device Stocks
Novocure Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.